Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib
is beneficial for the use in fibromyalgia. We intend to seek whether this medication may
improve psychiatric and rheumatologic parameters of the disease.